Amlin non-exec increases stake
A round-up of the biggest director deals today so far.
Amlin independent non-executive director Sir Mark Wrightson has invested nearly £20,000 in increasing his stake in the Lloyds' insurance firm.
Sir Mark bought 5,000 shares at 395.75p each, taking his stake to 13,888 shares. He also acquired 1,000 shares 395.26p a share in his position as a trustee of a trust. This non-beneficial interest cost just short of £4,000 more.
Sir Mark is a member of the Panel on Takeovers and Mergers and he is a non-executive director of Domino Printing Sciences
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Amlin posted a 39% slump in pre-tax profit to £107.6m for the six months to June 2010 following big claims for natural disasters, although it indicated its confidence going forward by upping the dividend by 11% to 7.2p a share.
The devastating earthquake in Chile and hurricane Xynthia in Europe both struck during February.
Top Director Buys
IFG Group (IFP) Director name: Mr Peter PriestleyAmount purchased: 39,834 @ 114.35p Value: £45,550
Property Recycling Group (PROP) Director name: Mr Paul RackhamAmount purchased: 200,000 @ 12.00p Value: £24,000
Amlin (AML) Director name: Sir Mark WrightsonAmount purchased: 5,000 @ 395.75p Value: £19,788
Home Retail Group (HOME) Director name: Mr Oliver StockenAmount purchased: 5,741 @ 215.88p Value: £12,394
Top Director Sells
Home Retail Group (HOME) Director name: Mr Terry DuddyAmount sold: 129,911 @ 212.91p Value: £276,594
Sign up to Money Morning
Our team, led by award winning editors, is dedicated to delivering you the top news, analysis, and guides to help you manage your money, grow your investments and build wealth.
-
What the Employment Rights Bill means for your job
New workplace reforms are set to give employees new rights to benefits and flexible working
By Marc Shoffman Published
-
GSK share price surges after $2.2bn Zantac drug settlement
GSK has settled lawsuits in the US that alleged the drugmaker’s now-discontinued heartburn drug Zantac triggered cancer
By Chris Newlands Published